Stock Scorecard



Stock Summary for Seres Therapeutics Inc (MCRB) - $0.37 as of 4/18/2025 9:07:04 AM EST

Total Score

7 out of 30

Safety Score

21 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for MCRB

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for MCRB

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for MCRB

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for MCRB

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for MCRB (21 out of 100)

Stock Price Rating (Max of 10) 1
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 4
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for MCRB

Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics ( MCRB ) Looks Ripe for a Turnaround 4/17/2025 1:35:00 PM
Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer 4/9/2025 11:00:00 AM
Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer - Kymera Therapeutics ( NASDAQ:KYMR ) 4/9/2025 11:00:00 AM
Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer 3/17/2025 11:05:00 AM
Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer - Zenas BioPharma ( NASDAQ:ZBIO ) 3/17/2025 11:05:00 AM
Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates 3/13/2025 11:00:00 AM
Human Microbiome Market Size to Surge to $4.85 Billion by 2031, Fuelled by Research and Innovation - Exclusive Report by The Insight Partners 2/6/2025 12:23:00 PM
Live Biotherapeutics Market Outlook 2034: Accelerating at 14% CAGR, Projected to Reach US$ 422.9 Million, Latest Report by TMR 1/22/2025 4:08:00 PM
Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale - Seres Therapeutics ( NASDAQ:MCRB ) 1/16/2025 12:00:00 PM
Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale 1/16/2025 12:00:00 PM

Financial Details for MCRB

Company Overview

Ticker MCRB
Company Name Seres Therapeutics Inc
Country USA
Description Seres Therapeutics, Inc., a microbiome therapeutic platform company, is involved in the development of bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company is headquartered in Cambridge, Massachusetts.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2024
Next Earnings Date 5/6/2025

Stock Price History

Last Day Price 0.37
Price 4 Years Ago 8.33
Last Day Price Updated 4/18/2025 9:07:04 AM EST
Last Day Volume 2,659,658
Average Daily Volume 1,171,535
52-Week High 1.53
52-Week Low 0.36
Last Price to 52 Week Low 2.78%

Valuation Measures

Trailing PE N/A
Industry PE 37.77
Sector PE 39.26
5-Year Average PE -3.28
Free Cash Flow Ratio 2.06
Industry Free Cash Flow Ratio 17.82
Sector Free Cash Flow Ratio 38.99
Current Ratio Most Recent Quarter 0.94
Total Cash Per Share 0.18
Book Value Per Share Most Recent Quarter 0.08
Price to Book Ratio 8.39
Industry Price to Book Ratio 9.37
Sector Price to Book Ratio 22.22
Price to Sales Ratio Twelve Trailing Months 390.27
Industry Price to Sales Ratio Twelve Trailing Months 88.13
Sector Price to Sales Ratio Twelve Trailing Months 24.77
Analyst Buy Ratings 4
Analyst Strong Buy Ratings 0

Share Statistics

Total Shares Outstanding 174,359,000
Market Capitalization 64,512,830
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 100.12%
Reported EPS 12 Trailing Months -0.81
Reported EPS Past Year 0.00
Reported EPS Prior Year -0.93
Net Income Twelve Trailing Months 136,001
Net Income Past Year 136,000
Net Income Prior Year -113,724,000
Quarterly Revenue Growth YOY -93.40%
5-Year Revenue Growth -100.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet

Total Cash Most Recent Quarter 30,793,000
Total Cash Past Year 30,793,000
Total Cash Prior Year 127,965,000
Net Cash Position Most Recent Quarter -79,207,000
Net Cash Position Past Year -79,207,000
Long Term Debt Past Year 110,000,000
Long Term Debt Prior Year 101,544,000
Total Debt Most Recent Quarter 110,000,000
Equity to Debt Ratio Past Year 0.11
Equity to Debt Ratio Most Recent Quarter 0.11
Total Stockholder Equity Past Year 13,784,000
Total Stockholder Equity Prior Year -44,856,000
Total Stockholder Equity Most Recent Quarter 13,784,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -148,989,000
Free Cash Flow Per Share Twelve Trailing Months -0.85
Free Cash Flow Past Year -148,989,000
Free Cash Flow Prior Year -125,329,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.06
MACD Signal -0.05
20-Day Bollinger Lower Band 0.52
20-Day Bollinger Middle Band 0.77
20-Day Bollinger Upper Band 1.02
Beta 2.53
RSI 28.93
50-Day SMA 0.87
150-Day SMA 2.92
200-Day SMA 4.32

System

Modified 4/17/2025 5:42:30 AM EST